Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells. Issue 2 (28th March 2016)

• Record Type: Journal Article
• Authors: Sharma, Bhawna; Varney, Michelle L.; Saxena, Sugandha; Wu, Lingyun; Singh, Rakesh K.
• Is Part Of: Cancer letters. Volume 372:Issue 2(2016)
• Page Start: 192
• Page End: 200
• Publication Date: 2016-03-28
• Subjects: Chemokines -- Therapy resistance -- CXCR2 -- Stem cell; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2015.12.011
• Languages: English
• ISSNs: 0304-3835

Abstract

Highlights: Differential regulation of CXCR2 ligands and stem cell-like and mesenchymal phenotypes depends on chemotherapy used. Drug-resistant cell lines formed smaller primary tumors but were highly metastatic. Targeting CXCR2 signaling may help circumvent therapy resistance in breast cancer. Abstract: CXCR2 and its ligands have been shown to play an important role in tumor angiogenesis, therapy resistance and progression. In this study, we investigated whether CXCR2 ligands are responsible for the survival advantage and metastasis of drug-resistant cells and examined the underlying mechanism(s) doxorubicin or paclitaxel resistant mammary tumor cells. Our results demonstrated that drug-resistant Cl66 cells upregulated CXCR2 ligands but downregulated expression of CXCR2. We observed delayed tumor growth but increased metastasis in mice using these drug-resistant cells. Furthermore, we observed differential upregulation of stem cell and mesenchymal markers in the doxorubicin and paclitaxel-resistant tumor cells. Abrogation of the CXCR2 signaling axis using CXCR2 ligand neutralization resulted in significant inhibition of drug-resistant cell growth. Together, our data suggest chemotherapy-specific differential regulation of CXCR2 ligands, stem cell-like and mesenchymal phenotypes, and enhanced metastasis in drug-resistant cells and targeting CXCR2 signaling, may help circumvent therapy resistance in breast cancer.